COMMUNIQUÉS West-GlobeNewswire

AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle
19/05/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN BREVET CHINOIS PROTÉGEANT LE MASITINIB DANS LE TRAITEMENT DU COVID-19 JUSQU'EN 2041, AJOUTANT AINSI UNE INDICATION SUPPLÉMENTAIRE BÉNÉFICIANT D'UNE PROTECTION À LONG TERME DE LA [...]
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
18/05/2025
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In [...]
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
18/05/2025
S lowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in [...]
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
18/05/2025
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-z Clinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, [...]
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
17/05/2025
Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH- [...]
Brain Cancer Canada Awards $68,000 Research Grant for Clinical Trial of Anti-Cancer Vaccine Targeting DIPG, the Most Aggressive Pediatric Brain Cancer
17/05/2025
TORONTO, May 17, 2025 (GLOBE NEWSWIRE) -- Today, on DIPG Awareness Day, Brain Cancer Canada is pleased to award $68,000 for an innovative research initiative led by Dr. Aru Narendran, MD, PhD, and Dr. Patrick Sipila, [...]
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
17/05/2025
Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D — potentially simultaneously addressing durability, adherence, and [...]
Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the American Society of Gene and Cell Therapy 28th Annual Meeting
17/05/2025
Presented new preclinical data in non-human primates (NHP) for alpha-1 antitrypsin deficiency (AATD) and phenylketonuria (PKU), where RNA Gene Writer achieved an estimated 76% and 70% editing in hepatocytes 1 , [...]
Kailo Under Review: Best Pain Patch on the Market? Where to Buy Flex Pain Relief Patches
17/05/2025
Discover the Breakthrough Wearable Tech That’s Disrupting the Pain Relief Market – Kailo Flex Patch Offers Drug-Free, Fast-Acting Support with Verified User Results Sandy, May 17, 2025 (GLOBE NEWSWIRE) -- In This [...]
Back to Life Complete Healthy Back System Under Review - Fix Back Pain Naturally
17/05/2025
A breakthrough natural back pain relief program designed by wellness expert Emily Lark, the Back to Life Complete Healthy Back System uses a proven 3-phase movement method to improve posture, realign the spine, and [...]
The Bone Density Solution Under Review: Blue Heron Health Osteoporosis Bone Health Guide by Shelly Manning
17/05/2025
The Bone Density Solution Under Review: Blue Heron Health Osteoporosis Bone Health Guide by Shelly Manning New York, May 16, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: Why osteoporosis and bone density [...]
Neuropathy No More Under Review: Blue Heron Health News' Nerve Pain Relief Tips Guide
17/05/2025
Natural Nerve Pain Relief Guide by Jodi Knapp Offers Holistic, Non-Pharmaceutical Approach to Peripheral Neuropathy—Emphasizing Gut Health, Lifestyle Changes, and Root-Cause Healing Beaverton, May 16, 2025 (GLOBE [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
16/05/2025
SAN CARLOS, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
NMDP℠ Partners with Lil Miquela to Encourage Young People to Join the Blood Stem Cell Donor Registry and Help Save Patient Lives
16/05/2025
A new campaign will portray the patient journey through the eyes of the virtual influencer, helping to educate and inspire her young fans to save a life through blood stem cell donation MINNEAPOLIS, May 16, 2025 (GLOBE [...]
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
16/05/2025
Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines [...]
Silo Pharma Announces Closing of $2 Million Public Offering
16/05/2025
SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16/05/2025
BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical [...]
4DMT Announces New Employment Inducement Grants
16/05/2025
EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/05/2025
SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from [...]

Pages